LLY

733.87

+2.71%↑

JNJ

149.53

+2.14%↑

UNH

273.23

-11.3%↓

ABBV

181.65

+2.56%↑

NVO

66.05

+2.69%↑

LLY

733.87

+2.71%↑

JNJ

149.53

+2.14%↑

UNH

273.23

-11.3%↓

ABBV

181.65

+2.56%↑

NVO

66.05

+2.69%↑

LLY

733.87

+2.71%↑

JNJ

149.53

+2.14%↑

UNH

273.23

-11.3%↓

ABBV

181.65

+2.56%↑

NVO

66.05

+2.69%↑

LLY

733.87

+2.71%↑

JNJ

149.53

+2.14%↑

UNH

273.23

-11.3%↓

ABBV

181.65

+2.56%↑

NVO

66.05

+2.69%↑

LLY

733.87

+2.71%↑

JNJ

149.53

+2.14%↑

UNH

273.23

-11.3%↓

ABBV

181.65

+2.56%↑

NVO

66.05

+2.69%↑

Search

Zai Lab Ltd ADR

Aperta

SettoreSettore sanitario

28.25 1.22

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

27.7

Massimo

28.37

Metriche Chiave

By Trading Economics

Entrata

33M

-48M

Vendite

-2.6M

106M

EPS

-0.45

Margine di Profitto

-45.487

Dipendenti

1,869

EBITDA

19M

-56M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+83.96% upside

Dividendi

By Dow Jones

Utili prossimi

5 ago 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-241M

3.1B

Apertura precedente

27.03

Chiusura precedente

28.25

Notizie sul Sentiment di mercato

By Acuity

23%

77%

56 / 382 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Very Strong Bearish Evidence

Zai Lab Ltd ADR Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

14 mag 2025, 23:40 UTC

Azioni calde

Stocks to Watch: UnitedHealth Group, Foot Locker, CoreWeave

14 mag 2025, 23:33 UTC

I principali Market Mover

UnitedHealth Group Shares Fall After WSJ Reports of Investigation for Possible Medicare Fraud

14 mag 2025, 23:25 UTC

I principali Market Mover

Biohaven Shares Down as FDA Extends PDUFA Data for Troriluzole

14 mag 2025, 23:25 UTC

Utili

Xero Lifts Fiscal Year Profit 30% on Higher Prices, Subscriber Growth -- Update

14 mag 2025, 22:58 UTC

Utili

Xero Lifts Fiscal Year Profit 30% on Higher Prices, Subscriber Growth

14 mag 2025, 21:35 UTC

Utili

Cisco Systems Names Patterson as CFO, Patel as President

14 mag 2025, 23:59 UTC

Discorsi di Mercato

Implications of Xero's Cost Outlook Aren't Clear -- Market Talk

14 mag 2025, 23:49 UTC

Discorsi di Mercato

Xero's Cost Outlook Likely to Prompt Downgrades -- Market Talk

14 mag 2025, 23:48 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

14 mag 2025, 23:48 UTC

Discorsi di Mercato

Nikkei May Decline on Profit-Taking After Recent Gains -- Market Talk

14 mag 2025, 23:47 UTC

Discorsi di Mercato

Gold Gains on Possible Technical Recovery -- Market Talk

14 mag 2025, 23:34 UTC

Acquisizioni, Fusioni, Takeovers

Agnico-Eagle Mines to Subscribe for 30M Voting Common Shares of Foran Mining in Non-Brokered Private Placement at C$3 a Share

14 mag 2025, 23:10 UTC

Utili

Xero Lifts FY Profit 30% on Higher Prices, Subscriber Growth -- Update

14 mag 2025, 23:07 UTC

Utili

CoreWeave Posts Strong Revenue and Wins Google as a Customer. Stock Still Dives on Outlook. -- Barrons.com

14 mag 2025, 23:00 UTC

Notizie principali

UnitedHealth Group Is Under Criminal Investigation for Possible Medicare Fraud -- WSJ

14 mag 2025, 22:43 UTC

Utili

Xero Lifts FY Profit 30% on Higher Prices, Subscriber Growth

14 mag 2025, 22:34 UTC

Utili

Xero Expects 1H Operating Expense Ratio to Be Higher Than 2H>XRO.AU

14 mag 2025, 22:33 UTC

Utili

Xero Expects FY26 Operating Expense Ratio of 71.5%>XRO.AU

14 mag 2025, 22:30 UTC

Utili

Xero Did Not Declare a Dividend>XRO.AU

14 mag 2025, 22:30 UTC

Utili

Xero FY Operating Expenses 71.8% of Operating Revenue Vs. 73.3%>XRO.AU

14 mag 2025, 22:30 UTC

Utili

Xero FY Free Cashflow Margin 24.1% Vs. 20.0%>XRO.AU

14 mag 2025, 22:30 UTC

Utili

Xero FY Free Cashflow NZD506.7M Vs. NZD342.1M>XRO.AU

14 mag 2025, 22:28 UTC

Utili

Xero FY Ebitda NZD638.5M Vs. NZD497.4M>XRO.AU

14 mag 2025, 22:28 UTC

Utili

Xero FY Adjusted Ebitda NZD640.6M Vs. NZD526.5M>XRO.AU

14 mag 2025, 22:27 UTC

Utili

Xero FY Rev NZD2.10B Vs. NZD1.71B >XRO.AU

14 mag 2025, 22:27 UTC

Utili

Xero FY Net NZD227.8M Vs. Net NZD174.6M >XRO.AU

14 mag 2025, 22:23 UTC

Notizie principali

Boeing, GE Aerospace Get Qatar Airways Order After Saudi AI Tech Deals -- 2nd Update

14 mag 2025, 22:15 UTC

Utili

Correction to Cisco Earnings Article -- WSJ

14 mag 2025, 21:48 UTC

Utili

CoreWeave Posts Strong Revenue but Stock Dives on Updated Outlook -- Barrons.com

14 mag 2025, 21:37 UTC

Utili

Cisco Reports Solid Earnings. The Stock Is Rising. -- Barrons.com

Confronto tra pari

Modifica del prezzo

Zai Lab Ltd ADR Previsione

Obiettivo di Prezzo

By TipRanks

83.96% in crescita

Previsioni per 12 mesi

Media 52.65 USD  83.96%

Alto 73 USD

Basso 32.6 USD

Basato su 6 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Zai Lab Ltd ADR - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

6 ratings

5

Acquista

1

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

28.13 / 31.12Supporto e resistenza

A breve termine

Very Strong Bearish Evidence

A termine intermedio

Bearish Evidence

A lungo termine

Bullish Evidence

Sentiment

By Acuity

56 / 382 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove rialziste molto forti

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sopra la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Zai Lab Ltd ADR

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT; and strategic collaboration with Pfizer for XACDURO. The company was incorporated in 2013 and is headquartered in Shanghai, China.